Ignyta Announces Presentations At The 2015 EORTC-National Cancer Institute-AACR Molecular Targets And Cancer Therapeutics Conference

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of four abstracts for poster presentations at the 27th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. The presentations relate to the company’s three clinical-stage product candidates, entrectinib, RXDX-105 and RXDX-107, and will be made on November 6-8, 2015.

Help employers find you! Check out all the jobs and post your resume.